Current issue
Archive
Online first
About the Journal
Editorial Office
Editorial Board
Publisher
Editorial Policies
Ethical standards and procedures
Abstracting and indexing
Reviewers
Honorary Reviewers
Subscription
Contact
Most read articles
Instructions for authors
Article processing charge (APC)
Books and Events
Books
Events
REVIEW PAPER
Sjögren’s syndrome versus IgG4-related diseases – classification difficulties and treatment progress
Submission date: 2014-03-22
Final revision date: 2014-07-12
Acceptance date: 2014-07-25
Online publication date: 2014-09-12
Publication date: 2014-08-31
Reumatologia 2014;52(4):255-262
KEYWORDS
TOPICS
ABSTRACT
Sjögren’s syndrome (SS) is a chronic autoimmune disorder characterized by lymphocytic infiltration in exocrine glands mainly salivary and lacrimal which affects impairment of their functions. Some patients develop extraglandular symptoms such as chronic fatigue, arthralgia, or lung, renal, central or peripheral nervous system involvement. Recent decades have brought understanding of some pathogenetic mechanisms and offered new therapeutic options by depleting B cells. Furthermore, the American College of Rheumatology proposed a new set of classification criteria based on objective symptoms. IgG4-related diseases are new nosological entities. The clinical course similarities of SS to Mikulicz’s disease (a subtype of IgG4-related disease) result in diagnostic difficulties. Typical conditions of them are: an increased IgG4 level and infiltrations of parenchymal organs by plasmatic cells. This review summarizes classification difficulties, pathogenesis and treatment strategies of SS and IgG4-related diseases.
REFERENCES (58)
1.
Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-558. .
2.
Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology classification criteria for Sjögren’s syndrome: a data-driven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 2012; 64: 475-487. .
3.
Whitcher JP, Shiboski CH, Shiboski SC, et al. A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjögren’s Syndrome International Registry. Am J Ophthalmol 2010; 149: 405-415. .
4.
Vitali C, Bootsma H, Bowman SJ. Classification criteria for Sjögren’s syndrome: we actually need to definitively resolve the long debate on the issue. Ann Rheum Dis 2013; 72: 476-478. .
5.
Rasmussen A, Ice JA, Li H, et al. Comparison of the American-European Consensus Group Sjogren’s syndrome classification criteria to newly proposed American College of Rheumatology criteria in a large, carefully characterized sicca cohort. Ann Rheum Dis 2014; 73: 31-38. .
6.
Yao Q, Wu G, Hoschar A. IgG4-related Mikulicz’s disease is a multiorgan lymphoproliferative disease distinct from Sjogren’s syndrome: a Caucasian patient and literature review. Clin Exp Rheumatol 2013; 31: 289-294. .
7.
Triantafyllias K, Karaiskaki N, Hansen T, et al. Interdisciplinary approach in a patient with IgG4-associated Mikulicz’s disease. Z Rheumatol 2013; 72: 916-920. .
8.
Masaki Y, Dong L, Kurose N, et al. Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis 2009; 68: 1310-1315. .
9.
Grygiel-Górniak B, Puszczewicz M Choroby IgG4-zależne – nowe spojrzenie w reumatologii. Reumatologia 2013; 51: 284-292. .
10.
Mavragani CP, Nezos A, Moutsopoulos HM. New advances in the classification, pathogenesis and treatment of Sjögren’s syndrome. Curr Opin Rheumatol 2013; 25: 623-629. .
11.
Saadoun D, Terrier B, Bannock J, et al. Expansion of autoreactive unresponsive CD21-/low B cells in Sjögren’s syndrome-associated lymphoproliferation. Arthritis Rheum 2013; 65: 1085-1096. .
12.
Quartuccio L, Salvin S, Fabris M, et al. BLyS upregulation in Sjögren’s syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology (Oxford) 2013; 52: 276-281. .
13.
Vakaloglou KM, Mavragani CP. Activation of the type I interferon pathway in primary Sjögren’s syndrome: an update. Curr Opin Rheumatol 2011; 23: 459-464. .
14.
Manoussakis MN, Boiu S, Korkolopoulou P, et al. Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjögren’s syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development. Arthritis Rheum 2007; 56: 3977-3988. .
15.
Mavragani CP, Moutsopoulos HM. The geoepidemiology of Sjögren’s syndrome. Autoimmun Rev 2010; 9: A305-310. .
16.
Okuma A, Hoshino K, Ohba T, et al. Enhanced apoptosis by disruption of the STAT3-IB- signaling pathway in epithelial cells induces Sjögren’s syndrome-like autoimmune disease. Immunity 2013; 38: 450-460. .
17.
Dawson L, Tobin A, Smith P, Gordon T. Antimuscarinic antibodies in Sjögren’s syndrome: where are we, and where are we going? Arthritis Rheum 2005; 52: 2984-2995. .
18.
Mavragani CP, Schini M, Gravani F, et al. Brief report: adrenal autoimmunity in primary Sjögren’s syndrome. Arthritis Rheum 2012; 64: 4066-4071. .
19.
Atzeni F, Sarzi-Puttini P, Lama N, et al. Anti-cyclic citrullinated peptide antibodies in primary Sjögren syndrome may be associated with non-erosive synovitis. Arthritis Res Ther 2008; 10: R51. .
20.
Ryu YS, Park SH, Lee J, et al. Follow-up of primary Sjögren’s syndrome patients presenting positive anti-cyclic citrullinated peptides antibody. Rheumatol Int 2013; 33: 1443-1446. .
21.
Kim SM, Park E, Lee JH, et al. The clinical significance of anti-cyclic citrullinated peptide antibody in primary Sjögren syndrome. Rheumatol Int 2012; 32: 3963-3967. .
22.
Haga HJ, Andersen DT, Peen E. Prevalence of IgA class antibodies to cyclic citrullinated peptide (anti-CCP) in patients with primary Sjögren’s syndrome, and its association to clinical manifestations. Clin Rheumatol 2011; 30: 369-372. .
23.
Bournia VK, Vlachoyiannopoulos PG. Subgroups of Sjögren syndrome patients according to serological profiles. J Autoimmun 2012; 39: 15-26. .
24.
Bournia VK, Diamanti KD, Vlachoyiannopoulos PG, Moutsopoulos HM. Anticentromere antibody positive Sjögren’s syndrome: a retrospective descriptive analysis. Arthritis Res Ther 2010; 12: R47. .
25.
Nakamura H, Kawakami A, Hayashi T, et al. Anti-centromere antibody-seropositive Sjögren’s syndrome differs from conventional subgroup in clinical and pathological study. BMC Musculoskelet Disord 2010; 11: 140. .
26.
Wu R, Shovman O, Zhang Y, et al. Increased prevalence of anti-third generation cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis and CREST syndrome. Clin Rev Allergy Immunol 2007; 32: 47-56. .
27.
Ferry JA, Deshpande V. IgG4-related disease in the head and neck. Semin Diagn Pathol 2012; 29: 235-244. .
28.
Yamamoto M, Takahashi H Shinomura Y, et al. Mechanisms and assessment of IgG4-related disease: lessons for the rheumatologist. Nat Rev Rheumatol 2014; 10: 143-159. .
29.
Tsuboi H, Matsuo N, Iizuka M, et al. Analysis of IgG4 class switch-related molecules in IgG4-related disease. Arthritis Res Ther 2012; 14: R171. .
30.
Ohta N, Kurakami K, Ishida A, et al. Roles of TGF-beta and periostin in fibrosclerosis in patients with IgG4-related diseases. Acta Otolaryngol 2013; 133: 1322-1327. .
31.
Conway SJ, Izuhara K, Kudo Y, et al. The role of periostin in tissue remodeling across health and disease. Cell Mol Life Sci 2014; 71: 1279-1288. .
32.
Ohta N, Ishida A, Kurakami K, et al. Expressions and roles of periostin in otolaryngological diseases. Allergol Int 2014; 68: 171-180. .
33.
Mavragani CP, Moutsopoulos HM. Conventional therapy of Sjögren’s syndrome. Clin Rev Allergy Immunol 2007; 32: 284-291. .
34.
Vitali C, Palombi G, Cataleta P. Treating Sjögren’s syndrome: insights for the clinician. Ther Adv Musculoskelet Dis 2010; 2: 155-166. .
35.
Moscovici BK, Holzchuh R, Chiacchio BB, et al. Clinical treatment of dry eye using 0.03% tacrolimus eye drops. Cornea 2012; 31: 945-949. .
36.
Ramos-Casals M, Tzioufas AG, Stone JH, et al. Treatment of primary Sjögren syndrome: a systematic review. JAMA 2010; 304: 452-460. .
37.
Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-445. .
38.
Parada-Turska J, Dudek P, Seweryn R, et al. Effectiveness and safety of the use of rituximab in patients with active rheumatoid arthritis – 5 years personal observations. Reumatologia 2013; 51: 20-25. .
39.
Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008; 67: 1541-1544. .
40.
Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome. Ann Rheum Dis 2007; 66: 351-357. .
41.
Mekinian A, Ravaud P, Hatron PY, et al. Efficacy of rituximab in primary Sjögren’s syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis 2012; 71: 84-87. .
42.
Mekinian A, Ravaud P, Larroche C, et al. Rituximab in central nervous system manifestations of patients with primary Sjögren’s syndrome: results from the AIR registry. Clin Exp Rheumatol 2012; 30: 208-212. .
43.
Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjögren’s syndrome: an open-label phase II study. Arthritis Rheum 2005; 52: 2740-2750. .
44.
Gottenberg JE, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 64: 913-920. .
45.
St Clair EW, Levesque MC, Prak ET, et al. Rituximab therapy for primary Sjögren’s syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheum 2013; 65: 1097-1106. .
46.
Voulgarelis M, Giannouli S, Anagnostou D, Tzioufas AG. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren’s syndrome-associated B-cell aggressive non-Hodgkin’s lymphomas. Rheumatology (Oxford) 2004; 43: 1050-1053. .
47.
Pijpe J, van Imhoff GW, Vissink A, et al. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjögren’s syndrome and associated MALT lymphoma. Ann Rheum Dis 2005; 64: 958-960. .
48.
Carnahan J, Stein R, Qu Z, et al. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol 2007; 44: 1331-1341. .
49.
Steinfeld SD, Tant L, Burmester GR, et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren’s syndrome: an open-label phase I/II study. Arthritis Res Ther 2006; 8: R129. .
50.
Norheim KB, Harboe E, Gøransson LG, Omdal R. Interleukin-1 inhibition and fatigue in primary Sjögren’s syndrome – a double blind, randomised clinical trial. PLoS One 2012; 7: e30123. .
51.
Wang D, Zhang H, Liang J, et al. Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. Cell Transplant 2013; 22: 2267-2277. .
52.
Christopeit M, Schendel M, Föll J, et al. Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L. Leukemia 2008; 22: 1062-1064. .
53.
Ezquer FE, Ezquer ME, Parrau DB, et al. Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. Biol Blood Marrow Transplant 2008; 14: 631-640. .
54.
Khalili S, Liu Y, Kornete M, et al. Mesenchymal stromal cells improve salivary function and reduce lymphocytic infiltrates in mice with Sjögren’s-like disease. PLoS One 2012; 7: e38615. .
55.
Doreian BW, Fulop TG, Meklemburg RL, Smith CB. Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren syndrome. Blood 2012; 20: 3142-3154. .
56.
Chen TS, Figueira E, Lau OC, et al. Successful “medical” orbital decompression with adjunctive rituximab for severe visual loss in IgG4-related orbital inflammatory disease with orbital myositis. Ophthal Plast Reconstr Surg 2014; Jan 29 [Epub ahead of print]. .
57.
Ingen-Housz-Oro S, Ortonne N, Chosidow O. IgG4-related skin disease-reply. JAMA Dermatol 2013; 149: 1440. .
58.
Maślińska M, Przygodzka M, Kwiatkowska B, Sikorska-Siudek K. Sjögren’s syndrome: still not fully understood disease. Rheumatol Int 2014; Jul 2 [Epub ahead of print].
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
